P
Philip Clingan
Researcher at University of Wollongong
Publications - 52
Citations - 8539
Philip Clingan is an academic researcher from University of Wollongong. The author has contributed to research in topics: Ramucirumab & Population. The author has an hindex of 17, co-authored 47 publications receiving 5964 citations. Previous affiliations of Philip Clingan include Illawarra Health & Medical Research Institute.
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
TL;DR: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
Thierry André,Corrado Boni,Matilde Navarro,Josep Tabernero,Tamas Hickish,C. Topham,Andrea Bonetti,Philip Clingan,John Bridgewater,Fernanado Rivera,Aimery de Gramont +10 more
TL;DR: Adding oxaliplatin to LV5FU2 significantly improved 5-year DFS and 6-year OS in the adjuvant treatment of stage II or III colon cancer and should be considered after surgery for patients with stage III disease.
Journal ArticleDOI
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,György Bodoky,Rocio Garcia-Carbonero,Tudor Ciuleanu,David Craig Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García-Alfonso,Kentaro Yamazaki,Philip Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao Chun Chang,F. Nasroulah +18 more
TL;DR: Ramucirumab plus F OLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma and toxic effects were manageable.
Journal ArticleDOI
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish M. Gadgeel,Delvys Rodriguez-Abreu,Giovanna Speranza,Emilio Esteban,Enriqueta Felip,Manuel Domine,Rina Hui,Maximilian Hochmair,Philip Clingan,Steven Francis Powell,Susanna Yee Shan Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Edward B. Garon,Silvia Novello,Belén Rubio-Viqueira,Michael Boyer,Takayasu Kurata,Jhanelle E. Gray,J. Yang,Tuba Bas,M. Catherine Pietanza,Marina Chiara Garassino +25 more
TL;DR: First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.
Journal ArticleDOI
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Ahmet Sezer,Saadettin Kilickap,Mahmut Gumus,Igor Bondarenko,Mustafa Ozguroglu,Miranda Gogishvili,Haci Mehmet Turk,Irfan Cicin,Dmitry Bentsion,Oleg Gladkov,Philip Clingan,Virote Sriuranpong,Naiyer A. Rizvi,Bo Gao,Siyu Li,S. Lee,Kristina McGuire,Chieh I. Chen,Tamta Makharadze,Semra Paydas,Marina Nechaeva,Frank Seebach,David M. Weinreich,George D. Yancopoulos,Giuseppe Gullo,Israel Lowy,P. Rietschel +26 more
TL;DR: In this paper, the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50% was examined in a multicentre, open-label, global, phase 3 study.